CN104642867A - 含双果糖酐的组合物 - Google Patents
含双果糖酐的组合物 Download PDFInfo
- Publication number
- CN104642867A CN104642867A CN201510036084.9A CN201510036084A CN104642867A CN 104642867 A CN104642867 A CN 104642867A CN 201510036084 A CN201510036084 A CN 201510036084A CN 104642867 A CN104642867 A CN 104642867A
- Authority
- CN
- China
- Prior art keywords
- dfa
- difructose anhydride
- bifidobacterium
- composition
- parts
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000008064 anhydrides Chemical class 0.000 title claims abstract description 21
- 239000000203 mixture Substances 0.000 title claims abstract description 17
- 241000186000 Bifidobacterium Species 0.000 claims description 13
- 241000186660 Lactobacillus Species 0.000 claims description 11
- 229940039696 lactobacillus Drugs 0.000 claims description 11
- 239000005913 Maltodextrin Substances 0.000 claims description 5
- 229920002774 Maltodextrin Polymers 0.000 claims description 5
- 229940035034 maltodextrin Drugs 0.000 claims description 5
- 230000000694 effects Effects 0.000 abstract description 7
- 239000006041 probiotic Substances 0.000 abstract 2
- 235000018291 probiotics Nutrition 0.000 abstract 2
- 238000001727 in vivo Methods 0.000 abstract 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 15
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid group Chemical group C(CC(O)(C(=O)O)CC(=O)O)(=O)O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 12
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 8
- RFCVXVPWSPOMFJ-UHFFFAOYSA-N 2-[(2-azaniumyl-3-phenylpropanoyl)amino]-4-methylpentanoate Chemical compound CC(C)CC(C(O)=O)NC(=O)C(N)CC1=CC=CC=C1 RFCVXVPWSPOMFJ-UHFFFAOYSA-N 0.000 description 7
- KSRQDWNGXKYIDO-UHFFFAOYSA-N difructose anhydride III Natural products O1C2C(O)C(CO)OC2(CO)OCC21OC(CO)C(O)C2O KSRQDWNGXKYIDO-UHFFFAOYSA-N 0.000 description 7
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical group C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 4
- 206010010774 Constipation Diseases 0.000 description 4
- 239000003613 bile acid Substances 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000004310 lactic acid Substances 0.000 description 4
- 235000014655 lactic acid Nutrition 0.000 description 4
- 238000009395 breeding Methods 0.000 description 3
- 230000001488 breeding effect Effects 0.000 description 3
- 230000013872 defecation Effects 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 206010009944 Colon cancer Diseases 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 235000013406 prebiotics Nutrition 0.000 description 2
- 235000013618 yogurt Nutrition 0.000 description 2
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000186012 Bifidobacterium breve Species 0.000 description 1
- 241001608472 Bifidobacterium longum Species 0.000 description 1
- 241001468229 Bifidobacterium thermophilum Species 0.000 description 1
- 241000252983 Caecum Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 241000194032 Enterococcus faecalis Species 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 240000001046 Lactobacillus acidophilus Species 0.000 description 1
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 description 1
- 244000199866 Lactobacillus casei Species 0.000 description 1
- 235000013958 Lactobacillus casei Nutrition 0.000 description 1
- 241001561398 Lactobacillus jensenii Species 0.000 description 1
- 201000010538 Lactose Intolerance Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 238000001069 Raman spectroscopy Methods 0.000 description 1
- 241000235342 Saccharomycetes Species 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- LPQOADBMXVRBNX-UHFFFAOYSA-N ac1ldcw0 Chemical compound Cl.C1CN(C)CCN1C1=C(F)C=C2C(=O)C(C(O)=O)=CN3CCSC1=C32 LPQOADBMXVRBNX-UHFFFAOYSA-N 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000000721 bacterilogical effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229940009291 bifidobacterium longum Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 210000004534 cecum Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 1
- 230000001906 cholesterol absorption Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 208000001130 gallstones Diseases 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229940039695 lactobacillus acidophilus Drugs 0.000 description 1
- 229940017800 lactobacillus casei Drugs 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 210000002229 urogenital system Anatomy 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 229940046001 vitamin b complex Drugs 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
- A23C9/127—Fermented milk preparations; Treatment using microorganisms or enzymes using microorganisms of the genus lactobacteriaceae and other microorganisms or enzymes, e.g. kefir, koumiss
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Microbiology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开了一种含双果糖酐的组合物，包含有双果糖酐和益生菌。本发明产品能有效提高体内益生菌的活性，口味独特。
Description
技术领域
本发明涉及一种含双果糖酐的组合物。
背景技术
现有的食品组合物，在营养搭配、口味等方面难以满足人们日益提高的要求，需要不断开发新的食品组合物，提升产品档次。
发明内容
本发明的目的在于提供一种提高体内益生菌的活性，口味独特的含双果糖酐的组合物。
本发明的技术解决方案是：
一种含双果糖酐的组合物，其特征是：包含有双果糖酐和益生菌。
所述的双果糖酐，是DFAⅠ、DFAⅡ、DFAⅢ、DFAⅥ或DFAⅤ。
所述益生菌是双歧杆菌、乳杆菌的一种或几种。
所述的含双果糖酐的组合物，由下列重量份组成：
DFA 15份
双歧杆菌 0.5份
乳杆菌 0.5份
低聚果糖 30份
酸度调节剂 0.5份
麦芽糊精 53.5份；
所述的DFA是DFAⅠ、DFAⅡ、DFAⅢ、DFAⅥ或DFAⅤ。
经常使用的酸度调节剂是柠檬酸，乙酸和乳酸。
本发明各主要组分的作用：
双果糖酐
（1）促进肠道有益微生物菌群的生长繁殖
体外实验表明典型肠道微生物如双歧杆菌和乳杆菌不吸收双果糖酐Ⅲ，但摄入双果糖酐Ⅲ可以促进这些益生菌的生产繁殖，双果糖酐Ⅲ的摄入增加了盲肠短链脂肪酸的含量，其中乙酸所占比例含量大大增加。
（2）改善便秘
50名健康但排便少有便秘倾向的成人作试验者连续摄入双果糖酐Ⅲ（3 g/d）一个月，结果所有受试者排便情况都得到改善，其中23人大幅改善。说明双果糖酐Ⅲ可有效改善便秘排泄物状态，避免因便秘对身体带来的伤害。
（3）预防结肠癌
次级胆汁酸是由初级胆汁酸在肠道中受细菌作用下生成的，是促发结肠癌和胆结石的因素之一。双果糖酐Ⅲ喂养大鼠，改变了粪便胆汁酸的成分，抑制了次级胆汁酸的生成并大大降低了次级胆汁酸的比例。因而双果糖酐Ⅲ是一种可预防结肠直肠癌的新型益生元。
益生菌
益生菌系一种对人体有益的细菌,它们可直接作为食品添加剂服用,以维持肠道菌群的平衡。迄今为止,科学家已发现的益生菌大体上可分成三大类,其中包括:①乳杆菌类(如嗜酸乳杆菌、干酪乳杆菌、詹氏乳杆菌、拉曼乳杆菌等);②双歧杆菌类(如长双歧杆菌、短双歧杆菌、卵形双歧杆菌、嗜热双歧杆菌等);③革兰氏阳性球菌(如粪链球菌、乳球菌、中介链球菌等)。此外,还有一些酵母菌与酶亦可归入益生菌的范畴。
益生菌的生理功能
1.防治有些人种普遍患有的乳糖不耐症(喝鲜奶时出现的腹胀、腹泻等症状)。
2.促进蛋白质、单糖及钙、镁等营养物质的吸收，产生维生素B族等大量有益物质。
3.使肠道菌群的构成发生有益变化，改善人体胃肠道功能，恢复人体肠道内菌群平衡，形成抗菌生物屏障，维护人体健康。
4、抑制腐败菌的繁殖，消解腐败菌产生的毒素，清除肠道垃圾。
5.抑制胆固醇吸收，降血脂、降血压作用。
6.免疫调节作用，增强人体免疫力和抵抗力。
7.抗肿瘤、预防癌症作用。
8.提高SOD酶活力，消除人体自由基，具抗衰老、延年益寿作用。
9.有效预防女性泌尿生殖系统细菌感染。
低聚糖：
难以被胃肠消化吸收，甜度低，热量低，基本不增加血糖和血脂。低聚糖类似水溶性植物纤维，能有效降低血清胆固醇、甘油三脂、游离脂肪酸的数量，对于因血脂高而引起的高血压、动脉硬化等一系列心血管疾病有较好的改善作用。进入大肠作为双歧杆菌的增殖因子，能有效地促进人体内双歧杆菌的生长繁殖，抑制腐败菌生长，长期食用可减缓衰老、通便、抑菌、防癌、减轻肝脏负担。
含有DFA的食品形式可以是粉末、液体、片剂、胶囊等，不受特殊限制。例如，可添加木糖醇、赤藓糖醇、异麦芽酮糖等制成保健食品，也可按照酸奶工艺制造成酸奶。
双果糖酐可促进双歧杆菌和乳杆菌的生产繁殖，提高体内益生菌的活性，并且可有效改善排便。本发明口味独特。
下面结合实施例对本发明作进一步说明。
具体实施方式
实施例1：
一种含双果糖酐的组合物，由下列重量份的成分组成：
DFA 15份
双歧杆菌 0.5份
乳杆菌 0.5份
低聚果糖 30份
酸度调节剂 0.5份
麦芽糊精 53.5份；
所述的DFA是DFAⅠ、DFAⅡ、DFAⅢ、DFAⅥ或DFAⅤ。
使用的酸度调节剂是柠檬酸、乙酸或乳酸。
实施例2：
一种含双果糖酐的组合物，由下列重量份的成分组成：
DFA 12份
双歧杆菌 0.8份
乳杆菌 0.6份
低聚果糖 17份
酸度调节剂 0.5份
麦芽糊精 57份；
所述的DFA是DFAⅠ、DFAⅡ、DFAⅢ、DFAⅥ或DFAⅤ。
使用的酸度调节剂是柠檬酸、乙酸或乳酸。
实施例3：
一种含双果糖酐的组合物，由下列重量份的成分组成：
DFA 8份
双歧杆菌 0.7份
乳杆菌 0.5份
低聚果糖 22份
酸度调节剂 0.4份
麦芽糊精 59份；
所述的DFA是DFAⅠ、DFAⅡ、DFAⅢ、DFAⅥ或DFAⅤ。
使用的酸度调节剂是柠檬酸、乙酸或乳酸。
Claims (4)
1.一种含双果糖酐的组合物，其特征是：包含有双果糖酐和益生菌。
2.根据权利要求1所述的含双果糖酐的组合物，其特征是：所述的双果糖酐，是DFAⅠ、DFAⅡ、DFAⅢ、DFAⅥ或DFAⅤ。
3. 根据权利要求1或2所述的含双果糖酐的组合物，其特征是：所述益生菌是双歧杆菌、乳杆菌的一种或几种。
4. 根据权利要求1或2所述的含双果糖酐的组合物，其特征是：由下列重量份组成：
DFA 15份
双歧杆菌 0.5份
乳杆菌 0.5份
低聚果糖 30份
酸度调节剂 0.5份
麦芽糊精 53.5份；
所述的DFA是DFAⅠ、DFAⅡ、DFAⅢ、DFAⅥ或DFAⅤ。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510036084.9A CN104642867A (zh) | 2015-01-26 | 2015-01-26 | 含双果糖酐的组合物 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510036084.9A CN104642867A (zh) | 2015-01-26 | 2015-01-26 | 含双果糖酐的组合物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104642867A true CN104642867A (zh) | 2015-05-27 |
Family
ID=53234918
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510036084.9A Pending CN104642867A (zh) | 2015-01-26 | 2015-01-26 | 含双果糖酐的组合物 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104642867A (zh) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1488269A (zh) * | 2002-10-08 | 2004-04-14 | 刘佳明 | 酸奶冲剂 |
| US20040194630A1 (en) * | 2001-08-31 | 2004-10-07 | Eberhard Stoppok | Beverage with storage-stable dietary fiber additive |
| CN1545936A (zh) * | 2003-12-01 | 2004-11-17 | 上海交大昂立股份有限公司 | 一种含有活性益生菌的食用组合物及其制备方法 |
| CN101897729A (zh) * | 2009-05-31 | 2010-12-01 | 金士力佳友(天津)有限公司 | 一种益生菌组合物及其制剂 |
-
2015
- 2015-01-26 CN CN201510036084.9A patent/CN104642867A/zh active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040194630A1 (en) * | 2001-08-31 | 2004-10-07 | Eberhard Stoppok | Beverage with storage-stable dietary fiber additive |
| CN1488269A (zh) * | 2002-10-08 | 2004-04-14 | 刘佳明 | 酸奶冲剂 |
| CN1545936A (zh) * | 2003-12-01 | 2004-11-17 | 上海交大昂立股份有限公司 | 一种含有活性益生菌的食用组合物及其制备方法 |
| CN101897729A (zh) * | 2009-05-31 | 2010-12-01 | 金士力佳友(天津)有限公司 | 一种益生菌组合物及其制剂 |
Non-Patent Citations (2)
| Title |
|---|
| 周景欣等: "双歧杆菌低聚果糖制剂对便秘人群肠道菌群的调整作用", 《中国微生态学杂志》 * |
| 孙怡等: "双果糖酐Ⅲ的生理功能及制备方法", 《中国食品添加剂》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Mitsuoka | Development of functional foods | |
| Sanchez et al. | Probiotic fermented milks: present and future | |
| Bedani et al. | Impact of inulin and okara on Lactobacillus acidophilus La-5 and Bifidobacterium animalis Bb-12 viability in a fermented soy product and probiotic survival under in vitro simulated gastrointestinal conditions | |
| Holzapfel et al. | Introduction to pre-and probiotics | |
| Hernández-Hernández et al. | Effect of prebiotic carbohydrates on the growth and tolerance of Lactobacillus | |
| EP1137424B9 (en) | Preparation which contains oligosaccharides and probiotics | |
| Fooks et al. | Probiotics as modulators of the gut flora | |
| CN105454966A (zh) | 改善胃肠道且提高免疫力的益生菌固体饮料及其制备方法 | |
| US20230137618A1 (en) | Novel bifidobacterium bacteria and composition including novel bifidobacterium bacteria | |
| JP6796070B2 (ja) | 難消化性成分を含む飲食品および大腸内水素ガス産生剤 | |
| CN104983746A (zh) | 一种复合益生菌及制备方法 | |
| CN113559131A (zh) | 一种用于改善肠胃的益生菌粉 | |
| Liu et al. | Efficacy of pasteurised yoghurt in improving chronic constipation: A randomised, double-blind, placebo-controlled trial | |
| US20210244777A1 (en) | Novel bifidobacterium bacteria and composition including novel bifidobacterium bacteria | |
| Rowland | Probiotics and benefits to human health—the evidence in favour. | |
| Onyenweaku et al. | Research Article Health Benefits of Probiotics | |
| Jain et al. | Significance of probiotics and prebiotics in health and nutrition | |
| JP2007082403A (ja) | ユッカ抽出物、キラヤ抽出物及び乳酸菌の複合組成物を含有する飲食品及びその製造法 | |
| Baek et al. | Probiotics and prebiotics as bioactive components in dairy products | |
| CN104642867A (zh) | 含双果糖酐的组合物 | |
| Chikkamath et al. | The role of probiotics, prebiotics and synbiotic on human health and disease-A review | |
| Kumar et al. | Health-promoting probiotic functional foods | |
| Berggren et al. | Intestinal function, microflora and nutrient intake of children after administration of a fermented oat product containing Lactobacillus plantarum DSM 9843 (299v) | |
| Nithya | A review on probiotics and prebiotics in foods | |
| Panggabean et al. | A naturally-stabilized-and-balanced synbiotics as a catalyst to aid in healing anti-microbial-resistance-induced communicable and non-communicable diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20150527 |